EUVIMEDEUVIMED entdecken
Open Access

HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial Cancer

Sherry Shen, Weining Ma, David Brown, Arnaud Da Cruz Paula, Qin Zhou, Alexia Iaosonos, Basile Tessier-Cloutier, Dara S Ross, Tiffany Troso-Sandoval, Jorge S Reis-Filho, Nadeem Abu-Rustum, Yanming Zhang und 4 weitere

Modern Pathology · 2023-11 · 36 (11) · 100299

DOI: 10.1016/j.modpat.2023.100299 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2023-11. Verfasst von Sherry Shen und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Carcinoma, Breast Neoplasms. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsCarcinomaBreast NeoplasmsFemaleHumansTrastuzumabAdo-Trastuzumab EmtansineIn Situ Hybridization, FluorescenceErb-b2 Receptor Tyrosine Kinases

Stichwörter der Autor:innen

HER2high-grade endometrial cancerintratumor heterogeneitytargeted therapytrastuzumabuterine serous cancer

Substanzen

TrastuzumabAdo-Trastuzumab EmtansineErb-b2 Receptor Tyrosine Kinases

Autor:innen und Institutionen

  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: chuim1@mskcc.org.

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Shen, S., Ma, W., Brown, D., Da Cruz Paula, A., Zhou, Q., Iaosonos, A., Tessier-Cloutier, B., Ross, D. S., Troso-Sandoval, T., Reis-Filho, J. S., Abu-Rustum, N., Zhang, Y., Ellenson, L. H., Weigelt, B., Makker, V., & Chui, M. H. (2023). HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial Cancer. Modern Pathology, 36(11), 100299. https://doi.org/10.1016/j.modpat.2023.100299

Vancouver

Shen S, Ma W, Brown D, Da Cruz Paula A, Zhou Q, Iaosonos A, et al. HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial Cancer. Modern Pathology. 2023;36(11):100299. doi:10.1016/j.modpat.2023.100299

BibTeX
@article{Shen2023,
  author = {Shen, Sherry and Ma, Weining and Brown, David and Da Cruz Paula, Arnaud and Zhou, Qin and Iaosonos, Alexia and Tessier-Cloutier, Basile and Ross, Dara S and Troso-Sandoval, Tiffany and Reis-Filho, Jorge S and Abu-Rustum, Nadeem and Zhang, Yanming and Ellenson, Lora H and Weigelt, Britta and Makker, Vicky and Chui, M Herman},
  title = {HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial Cancer},
  journal = {Modern Pathology},
  year = {2023},
  volume = {36},
  number = {11},
  pages = {100299},
  doi = {10.1016/j.modpat.2023.100299}
}
Kostenlos starten →